Significantly Reduced the Need for SCS Use or Sino‑Nasal Surgery vs Placebo in a Prespecified Multiplicity-Controlled Pooled Analysis of SINUS‑24 and SINUS‑521,2,a
TIME TO FIRST SCS USE OR CRSwNP SURGERY DURING THE TREATMENT PERIOD


Fewer Patients Required
SCS Use at Week 52
SCS Use at Week 52
(HR: 0.26 [95% CI: 0.18, 0.38])1
- 75% REDUCTION IN SCS COURSES PER YEAR
(RR: 0.25 [95% CI: 0.17, 0.37])1


Fewer Patients Required
sino-nasal
surgery at week 52
sino-nasal
surgery at week 52
(HR: 0.17 [95% CI: 0.07, 0.46])1
aIndividually, SCS reduction and need for sino-nasal surgery were not multiplicity-adjusted endpoints.3
HR, hazard ratio; RR, risk ratio.
Explore the Safety Data and Study Designs
Dosage and
Administration
Administration
See the recommended dosing and
administration options for patients
on DUPIXENT.